412 related articles for article (PubMed ID: 27123176)
1. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
3. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
4. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
5. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Qiu T; Liang S; Wang Y; Dussart C; Borissov B; Toumi M
Front Public Health; 2021; 9():754482. PubMed ID: 34900902
[TBL] [Abstract][Full Text] [Related]
6. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
Detela G; Lodge A
Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
[TBL] [Abstract][Full Text] [Related]
7. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
8. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
9. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
10. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
11. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.
Horgan D; Metspalu A; Ouillade MC; Athanasiou D; Pasi J; Adjali O; Harrison P; Hermans C; Codacci-Pisanelli G; Koeva J; Szucs T; Cursaru V; Belina I; Bernini C; Zhuang S; McMahon S; Toncheva D; Thum T
Biomed Hub; 2020; 5(3):130-152. PubMed ID: 33987187
[TBL] [Abstract][Full Text] [Related]
12. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
13. Managing access to advanced therapy medicinal products: Challenges for NHS Wales.
Champion AR; Lewis S; Davies S; Hughes DA
Br J Clin Pharmacol; 2021 Jun; 87(6):2444-2449. PubMed ID: 32495405
[TBL] [Abstract][Full Text] [Related]
14. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries.
Gozzo L; Romano GL; Romano F; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():755052. PubMed ID: 34690785
[TBL] [Abstract][Full Text] [Related]
16. What are the Changes in 2023 for Access to Advanced Therapy Medicinal Products (ATMPs) in France?
Bartos B
Eur J Health Law; 2024 Jan; 31(2):187-208. PubMed ID: 38280386
[TBL] [Abstract][Full Text] [Related]
17. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
18. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
19. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
